Aprogen Medicines Statistics

Total Valuation

Aprogen Medicines has a market cap or net worth of KRW 223.06 billion. The enterprise value is 607.77 billion.

Market Cap	223.06B
Enterprise Value	607.77B

Important Dates

The next estimated earnings date is Thursday, March 20, 2025.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Aprogen Medicines has 278.82 million shares outstanding. The number of shares has increased by 6.94% in one year.

Current Share Class	n/a
Shares Outstanding	278.82M
Shares Change (YoY)	+6.94%
Shares Change (QoQ)	+4.94%
Owned by Insiders (%)	7.67%
Owned by Institutions (%)	2.26%
Float	146.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.35
PB Ratio	1.73
P/TBV Ratio	1.92
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-14.38
EV / Sales	4.11
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.82

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.26.

Current Ratio	1.36
Quick Ratio	0.62
Debt / Equity	0.26
Debt / EBITDA	n/a
Debt / FCF	-1.84
Interest Coverage	-21.11

Financial Efficiency

Return on equity (ROE) is -19.69% and return on invested capital (ROIC) is -9.95%.

Return on Equity (ROE)	-19.69%
Return on Assets (ROA)	-8.94%
Return on Capital (ROIC)	-9.95%
Revenue Per Employee	603.48M
Profits Per Employee	-172.53M
Employee Count	245
Asset Turnover	0.24
Inventory Turnover	1.22

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.71% in the last 52 weeks. The beta is 0.83, so Aprogen Medicines's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	-14.71%
50-Day Moving Average	1,039.90
200-Day Moving Average	1,301.13
Relative Strength Index (RSI)	34.25
Average Volume (20 Days)	5,511,921

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Aprogen Medicines had revenue of KRW 147.85 billion and -42.27 billion in losses. Loss per share was -170.24.

Revenue	147.85B
Gross Profit	59.66B
Operating Income	-87.05B
Pretax Income	-84.28B
Net Income	-42.27B
EBITDA	-58.45B
EBIT	-87.05B
Loss Per Share	-170.24

Full Income Statement

Balance Sheet

The company has 49.70 billion in cash and 113.88 billion in debt, giving a net cash position of -64.18 billion or -230.18 per share.

Cash & Cash Equivalents	49.70B
Total Debt	113.88B
Net Cash	-64.18B
Net Cash Per Share	-230.18
Equity (Book Value)	443.27B
Book Value Per Share	461.24
Working Capital	43.07B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -51.07 billion and capital expenditures -10.81 billion, giving a free cash flow of -61.88 billion.

Operating Cash Flow	-51.07B
Capital Expenditures	-10.81B
Free Cash Flow	-61.88B
FCF Per Share	-221.92

Full Cash Flow Statement

Margins

Gross margin is 40.35%, with operating and profit margins of -58.88% and -28.59%.

Gross Margin	40.35%
Operating Margin	-58.88%
Pretax Margin	-57.00%
Profit Margin	-28.59%
EBITDA Margin	-39.53%
EBIT Margin	-58.88%
FCF Margin	n/a

Dividends & Yields

Aprogen Medicines does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.94%
Shareholder Yield	-6.94%
Earnings Yield	-21.28%
FCF Yield	-27.74%

Stock Splits

The last stock split was on December 28, 2022. It was a reverse split with a ratio of 0.3333333333.

Last Split Date	Dec 28, 2022
Split Type	Reverse
Split Ratio	0.3333333333

Scores

Aprogen Medicines has an Altman Z-Score of -0.05. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.05
Piotroski F-Score	n/a